BioWorld

May 17, 2006

View Archived Issues

Neurocrine Shares Dumped As FDA Sets Back Indiplon

The FDA delayed approving an immediate-release version of the sleep drug indiplon and rejected a modified-release formulation, actions that on Tuesday crushed the stock of Neurocrine Biosciences Inc. (BioWorld Today) Read More

Intercept Brings In $41M To Target FXR In Liver Disease

Read More

Dyax Plunges On Warning Of More Work With DX-88

Read More

Viron Raises $25M In Series A For Viral Protein Therapeutics

Read More

Clinic Roundup

Read More

Other News To Note

Read More